Skip to main content

Brintellix (Vortioxetine) and Brilinta (Ticragelor) & Medication Errors

    Basic Details
    Last Updated
    Thursday, February 29, 2024
    Original Posting Date
    Health Outcome(s)
    medication error
    Drug Use
    Meets requirements of FD&C Act Sec 505(o) prior to requiring a PMR
    Regulatory Determination / Use

    In July 2015, FDA released a drug safety communication regarding prescribing or dispensing errors due to brand name confusion with the antidepressant Brintellix (vortioxetine) and the antiplatelet Brilinta (ticagrelor). In May 2016, FDA approved a brand name change for the antidepressant Brintellix to Trintellix.


    This study was intended to explore Sentinel’s ability to detect potential drug name confusion errors using Brintellix-Brilinta as a feasibility use case. We developed a claims-based algorithm for identifying potential drug name confusion errors. In combination with claims profile review, we identified likely errors in both Brintellix and Brilinta users. This study demonstrated that a claims‐based algorithm combined with manual review of claims profiles could be used to identify potential drug name confusion errors.